Claudia Ferrara Koller

This inventor holds 24 USPTO granted patents and 33 published patent applications, plus 4 CIPO patents and 24 EPO patents, primarily in Cancer Immunotherapy. Top assignees: Hoffmann-La Roche Inc., Roche Glycart Ag, F. Hoffmann-La Roche Ag. Active years: 2016-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Claudia Ferrara Koller. Retrieved from https://idiyas.com/inventor/claudia-ferrara-koller

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 24 (Patent Applications = 33)

% Patents Active = 91.7

CIPO Patents = 4 (Patent Applications = 15)

EPO Patents = 24 (Patent Applications = 34)

Average Co-Inventor Count = 7.3

ph-index = 9

Forward Citations = 172(Granted Patents)

Location History:

Schlieren, CH (2020 - 2023)
Zug, CH (2016 - 2024)

Company Filing History:

18 out of 5,026

Hoffmann-La Roche Inc.

F. Hoffmann-La Roche Ag

patents

Years Active: 2016-2026

Loading Chart...

Areas of Expertise:

Bispecific Antibodies

4-1BB Agonists

TNF Family Ligands

Combination Therapy

Antigen Binding Molecules

Humanized Antibodies

DR5 Specific Antibodies

HER2-targeting

Tumor Necrosis Factor

Polynucleotides

Anti-CD19 Antibodies

FAP Specific Antibodies

24 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12723084 - 4-1BBL TRIMER-CONTAINING ANTIGEN BINDING MOLECULES (2026-09-01),

2. 12590151 - ANTI-HUMAN CD19 ANTIBODIES WITH HIGH AFFINITY (2026-03-31),

3. 12565530 - COMBINATION THERAPY WITH TARGETED 4-1BB (CD137) AGONISTS/ANTI-FAP BINDING DOMAIN AND ANTI-CEA/ANTI-CD3 BISPECIFIC ANTIBODY (2026-03-03),

4. 12441812 - Methods of treating cancer by administering tumor necrosis factor (TNF) family ligand trimer-containing antigen-binding molecules (2025-10-14),

5. 12281153 - Combination therapy with targeted 4-1BB (CD137) agonists (2025-04-21),

6. 12240911 - Bispecific antibodies specific for OX40 (2025-03-04),

7. 12227594 - Bispecific 2+1 contorsbodies (2025-02-18),

8. 12215152 - Humanized anti-human CD19 antibodies and methods of use (2025-02-04),

9. 12202870 - Antigen binding molecules comprising a trimeric TNF family ligand and encoding polynucleotides thereof (2025-01-21),

10. 12065478 - HER2-targeting antigen binding molecules comprising 4-1BBL (2024-08-20),

11. 11718680 - Combination therapy of anti-CD20/anti-CD3 bispecific antibodies and 4-1BB (CD137) agonists (2023-08-08),

12. 11447558 - Bispecific antigen binding molecules comprising anti-4-1BB clone 20H4.9 (2022-09-20),

13. 11306154 - Methods of treating cancer by administering antigen-binding molecules comprising a TNF family ligand trimer (2022-04-19),

14. 11286300 - Humanized anti-human CD19 antibodies and methods of use (2022-03-29),

15. 11267903 - Antigen-binding molecules comprising a tumor necrosis factor (TNF) family ligand trimer (2022-03-08),

Title: The Innovative Mind of Claudia Ferrara Koller: A Leader in Biopharmaceutical Patents

Introduction

Claudia Ferrara Koller is a prominent inventor based in Zug, Switzerland, known for her significant contributions to the field of biopharmaceuticals. With a remarkable portfolio of 20 patents, her work primarily focuses on innovative therapies for cancer treatment, enhancing the efficacy of existing medications, and developing novel therapeutic agents.

Latest Patents

Among her most recent patents, Claudia has developed notable inventions that underscore her expertise in combination therapies. One such patent involves a combination therapy with targeted 4-1BB (CD137) agonists. This invention relates to employing 4-1BB (CD137) agonists, particularly those containing antigen binding molecules, used alongside HER-2 targeting agents aimed at treating cancer. Another significant invention is her patent for bispecific antibodies specific for OX40. This innovation features new bispecific antigen binding molecules that consist of components capable of binding to target cell antigens, as well as a costimulatory TNF receptor family member. The patent also details the production methods and applications for these molecules.

Career Highlights

Throughout her career, Claudia has been associated with leading organizations in the biotech industry, notably Hoffmann-La Roche Inc. and Roche Glycart AG. Her work in these innovative companies has contributed to advancing the fields of immunotherapy and cancer treatment. Claudia's extensive knowledge and inventiveness have made her a key player in the development of transformative biopharmaceutical solutions.

Collaborations

Claudia has collaborated with esteemed professionals in her field, including Christian Klein and Pablo Umana. These partnerships have allowed her to exchange insights and foster innovations that reinforce her reputation as a distinguished inventor.

Conclusion

Claudia Ferrara Koller continues to make strides in biopharmaceutical innovation through her pioneering patents and collaborative efforts. Her dedication to developing novel therapies for cancer underscores her role as a leader in the field, paving the way for future advancements in treatment options. Her impressive record of patents reflects her commitment to improving patient outcomes and the ongoing battle against cancer.

Profile summary based on public USPTO records.